CurrentCareSourcePolicy N/A

Saphnelo (anifrolumab-fnia) — coverage criteria for systemic lupus erythematosus

This policy governs prior authorization and medical necessity criteria for Saphnelo (intravenous anifrolumab-fnia) for treatment of moderate to severe systemic lupus erythematosus (SLE) in adults receiving standard therapy, including initial and continuation approval conditions and dosing.

Policy Summary

PayerCareSource

PolicySaphnelo (anifrolumab-fnia) — coverage criteria for systemic lupus erythematosus

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date

Next Review DateMar 13, 2024

Key ActionObtain prior authorization and document patient age (≥18), autoantibody-positive SLE, concurrent standard therapy or intolerance, specialist involvement, and for continuation therapy evidence of clinical response.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

300 mgrecommended intravenous dose every 4 weeks

6 monthsinitial approval duration

1 yearcontinuation approval

≥18age requirement

NCapplicable state

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Saphnelo (anifrolumab-fnia)

Initial Therapy Criteria

Covered when ALL of the following are met for INITIAL therapy (approve 6 months):

Initial Therapy (approve 6 months)

Patient is >= 18 years of age>= 18 years
Patient has autoantibody-positive SLE, defined as positive for at least one of: antinuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA) antibodies, or anti-Smith (anti-Sm) antibodies
Concurrent standard therapy or intolerance
- Medication is used concurrently with at least one standard therapy (examples: antimalarial such as hydroxychloroquine; systemic corticosteroid such as prednisone; or other immunosuppressants such as azathioprine, mycophenolate mofetil, methotrexate)
- Patient is intolerant to standard therapy due to significant toxicity, as determined by the prescriber
Medication is prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist, or dermatologist
Approve initial course for 6 months

Operational note: Examples of standard therapies include hydroxychloroquine, systemic corticosteroids, azathioprine, mycophenolate mofetil, and methotrexate.

Continuation Therapy Criteria

Covered when ALL of the following are met for CONTINUATION therapy (approve 1 year):

Continuation Therapy (approve 1 year)

Patient is currently receiving Saphnelo
Medication is prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist, or dermatologist
Patient has demonstrated response to Saphnelo as determined by the prescriber (examples include reduction in flares; reduction in corticosteroid dose; hematologic, vascular, or organ-specific improvements; decrease in anti-dsDNA titer; improvement in complement C3/C4)

Use of Saphnelo is not recommended for patients with severe active lupus nephritis or severe active central nervous system (CNS) lupus. The product’s efficacy has not been evaluated in these populations and the policy explicitly states these situations are excluded from recommended approval.

Concurrent use of Saphnelo with other biologic agents is not recommended. Requests involving combination biologic therapy (for example, belimumab or rituximab) have not been studied; safety and efficacy for such combinations have not been established and may result in denial.

Coverage is not recommended for circumstances that are not described in the Recommended Authorization Criteria. This includes combination use of Saphnelo with other biologic therapies — safety and efficacy of such combinations have not been established and these situations should be considered not medically necessary under this policy.

See the policy appendix for examples of biologic agents (e.g., belimumab, rituximab and others) that should not be used concurrently with Saphnelo; combination therapy requests may be denied.

Dosing, Age, and Code References

Dosing guidance (no billing codes listed)mixed

NDC/HCPCS not specified

Policy lists recommended dosing: 300 mg IV every 4 weeks but does not provide specific HCPCS or NDC billing codes.

Other biologics (examples)mixed

examples

Appendix lists multiple biologic agents (adalimumab, certolizumab, etanercept, infliximab, golimumab, tocilizumab, rituximab, anakinra, ustekinumab, secukinumab, ixekizumab, tildrakizumab, risankizumab, guselkumab, vedolizumab) that should not be combined with Saphnelo; specific billing codes are not provided.

inv-07: Age — eligibility

Minimum ageAdults ≥ 18 years

Source phrasingPatient is ≥ 18 years of age

Approval implicationMeets age requirement for initial (6 months) and continuation (1 year) authorization if other criteria are met

Provider Requirements and Documentation

Prior Authorization

Prior Authorization Recommended

Prior Authorization is recommended for medical benefit coverage of Saphnelo. Approval is recommended for those who meet the Criteria and Dosing for the listed indication. All approvals are provided for the duration noted in the policy. Requests for doses outside the established dosing will be considered on a case‑by‑case basis by a clinician (Medical Director or Pharmacist). Because of the specialized skills required for evaluation, diagnosis, and monitoring, Saphnelo must be prescribed by or in consultation with a specialist (rheumatologist, clinical immunologist, nephrologist, neurologist, or dermatologist).

Approval durations: Initial therapy — 6 months; Continued therapy — 1 year
Specialist prescriber or documented consultation required

Note

Position Relative to Standard Therapies

Saphnelo is intended as add‑on therapy to standard SLE treatments. For initial therapy, the medication must be used concurrently with at least one standard therapy (examples: hydroxychloroquine, systemic corticosteroids such as prednisone, or immunosuppressants like azathioprine, mycophenolate mofetil, or methotrexate), or the patient must be documented intolerant to standard therapy. For patients currently receiving Saphnelo, continued approval requires documentation of clinical response (e.g., reduction in flares, decreased corticosteroid dose, improvement in serologic markers such as decreased anti‑dsDNA or improved complement C3/C4) and that the patient is receiving Saphnelo with concurrent standard therapy or has intolerance to such therapy.

Key Definitions

inv-13: Autoantibody-positive SLE — qualifying serologies

DefinitionAutoantibody‑positive SLE: positive for at least one of the following serologies: antinuclear antibodies (ANA), anti‑double‑stranded DNA (anti‑dsDNA), or anti‑Smith (anti‑Sm)

Clinical noteNot all patients with SLE are positive for anti‑dsDNA, but most will be positive for ANA

Role in approvalRequired for initial therapy authorization (one of the specified autoantibodies must be positive)

inv-14: Severe active nephritis/CNS lupus — definition and exclusion rationale

Definition / exclusionSevere active lupus nephritis or severe active central nervous system (CNS) lupus — Saphnelo efficacy has not been evaluated and use is not recommended

Policy consequenceRequests for Saphnelo in these populations are not recommended for approval

Background on Saphnelo (anifrolumab-fnia)

Saphnelo (anifrolumab-fnia) is a type I interferon receptor antagonist indicated for the treatment of moderate to severe systemic lupus erythematosus (SLE) in adults who are receiving standard therapy. The recommended intravenous dosing in the policy is 300 mg every 4 weeks as part of medical benefit administration.

The policy specifies that Saphnelo is intended for adults ≥18 years of age and should be used as an add-on to at least one standard therapy (for example, hydroxychloroquine, systemic corticosteroids, azathioprine, mycophenolate mofetil, or methotrexate) or for patients intolerant to standard therapy. Efficacy has not been evaluated in patients with severe active lupus nephritis or severe active CNS lupus; use in those populations is not recommended.